When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
JNJ - J&J's Darzalex shows treatment effect in mid-stage study in certain MM patients
Johnson & Johnson
Genmab A/S (OTCPK:GNMSF-2.3%) announces that a Phase 2 clinical trial, GRIFFIN, evaluating licensee Johnson & Johnson (JNJ+0.3%) unit Janssen Biotech's Darzalex (daratumumab), combined with Celgene's Revlimid (lenalidomide), Takeda's Velcade (bortezomib) and dexamethasone (VRd), in newly diagnosed multiple myeloma patients eligible for high-dose chemo and autologous stem cell transplantation met the primary endpoint.
More news on: Johnson & Johnson, Genmab A/S, Genmab A/S, Healthcare stocks news,